...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The journal of clinical psychiatry >Assessing the Risk Factors for Difficult-to-Treat Depression and Treatment-Resistant Depression
【24h】

Assessing the Risk Factors for Difficult-to-Treat Depression and Treatment-Resistant Depression

机译：评估难以治疗抑郁和治疗抑制的危险因素

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Depression is the leading cause of disability among people across the globe, according to the World Health Organization. Among those who have been diagnosed, many fail to achieve remission after following recommended antidepressant medication and psychosocial therapies. In particular, difficult-to-treat and treatment-resistant depression may cause severe impairments for patients, including diminished cognitive functioning, increased medical bills, and decreased workplace performance, as well as an increased risk of developing comorbid illnesses. However, many tools are available to clinicians for identifying treatment-resistant depression, including rating scales such as the 9-question Patient Health Questionnaire (PHQ-9) and the Quick Inventory of Depressive Symptomatology (QIDS-SR16), as well as clinical evidence related to risk factors for difficult-to-treat or treatment-resistant depression. Accurately identifying treatment-resistant depression is the first step toward changing treatment regimens to help patients achieve remission.
机译：据世界卫生组织称，抑郁症是全球人民中残疾的主要原因。在被诊断患者中，许多人在推荐的抗抑郁药物和心理社会治疗后未能达到缓解。特别地，难以治疗和治疗的抑制可能对患者造成严重的损伤，包括减少认知功能，增加医疗费用和减少工作场所性能，以及开发合并疾病的风险增加。然而，临床医生可以使用许多工具来识别治疗抗抑郁，包括评级尺度，如9质疑患者健康问卷（PHQ-9）和抑郁症状的快速库存（QIDS-SR16）以及临床证据与难以治疗或治疗抑制的风险因素有关。准确识别治疗抑制是改变治疗方案的第一步，帮助患者达到缓解。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号